Integra LifeSciences Holdings Co. (NASDAQ:IART) Short Interest Down 6.1% in December

Integra LifeSciences Holdings Co. (NASDAQ:IART) was the target of a large drop in short interest in December. As of December 31st, there was short interest totalling 3,240,000 shares, a drop of 6.1% from the December 15th total of 3,450,000 shares. Based on an average trading volume of 786,000 shares, the short-interest ratio is currently 4.1 days. Currently, 4.9% of the shares of the stock are short sold.

Insider Buying and Selling

In related news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors have recently made changes to their positions in IART. KBC Group NV raised its stake in shares of Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares during the period. Nisa Investment Advisors LLC grew its holdings in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after buying an additional 2,800 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Integra LifeSciences during the second quarter valued at about $114,000. Northwest Investment Counselors LLC purchased a new stake in shares of Integra LifeSciences in the third quarter worth about $73,000. Finally, Romano Brothers AND Company bought a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $204,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on IART shares. Truist Financial lowered their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America reduced their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. Citigroup lifted their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley began coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Stock Performance

NASDAQ:IART traded up $0.86 during trading hours on Friday, hitting $24.10. 762,836 shares of the company traded hands, compared to its average volume of 463,388. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The firm’s 50-day simple moving average is $23.20 and its 200-day simple moving average is $22.45. Integra LifeSciences has a one year low of $16.81 and a one year high of $45.42.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences’s revenue was down .4% on a year-over-year basis. During the same period last year, the business posted $0.76 earnings per share. As a group, equities research analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.